ViiV Healthcare to Conduct Phase 3b Clinical Trial Comparing Dovato and Biktarvy for HIV Treatment
Clinical Design and Objectives of the VOGUE Study
ViiV Healthcare is leading the VOGUE Phase 3b clinical trial (NCT05979311), which focuses on adult participants with HIV-1 infection who have no prior experience with antiretroviral therapy (ART). This study is designed to directly compare the virologic efficacy of Dovato, a two-drug regimen containing dolutegravir/lamivudine, and Biktarvy, a three-drug regimen containing bictegravir/emtricitabine/tenofovir alafenamide. The trial aims to demonstrate non-inferiority compared to existing standard treatments, which can be interpreted as a strategic effort to solidify the position of two-drug regimens in the initial stages of HIV treatment. The study, which involves approximately 473 participants, focuses on determining whether it can provide the same efficacy while reducing the burden of medication.
Differences in Drug Composition and Mechanism of Action
Dovato, a two-drug regimen, consists of dolutegravir, an integrase strand transfer inhibitor (INSTI), and lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). In contrast, Biktarvy, the comparator drug, is a three-drug regimen that combines bictegravir, an integrase inhibitor, with two reverse transcriptase inhibitors, emtricitabine and tenofovir alafenamide. ViiV Healthcare aims to significantly reduce the risk of drug toxicity and the emergence of resistance mutations that may occur with long-term use by reducing the number of drugs. This is an important mechanistic difference that can alleviate concerns about side effects such as kidney and bone density damage in HIV patients who need to take medication for life.
Introduction of Patient-Centric Evaluation Metrics
This trial goes beyond simply evaluating the biological suppression rate by lowering the viral load in the blood; it also measures patient-reported outcomes (PROs) and treatment adherence. This is to comprehensively assess the impact of improved medication convenience and quality of life (QoL) on long-term treatment adherence in real-world clinical settings. The study aims to demonstrate that reducing the number of pills and components from three to two can contribute to alleviating the patient's emotional burden and improving medication adherence. Ultimately, demonstrating its usefulness in real-world clinical settings is essential for expanding market share, making this a very realistic approach.
Market Competition and Changes in Guidelines
The global HIV treatment market is currently a large market with an annual value of over $34 billion. The market leader is Biktarvy from Gilead Sciences, which dominates the market with annual sales of approximately $14.3 billion as of 2025. In contrast, Dovato from ViiV Healthcare recorded sales of approximately £2.678 billion (approximately $3.4 billion) in 2025, showing rapid growth, but there is still a significant gap. If Dovato demonstrates non-inferiority to Biktarvy in this head-to-head clinical trial, it will be a decisive turning point in shifting the focus of global treatment guidelines from three-drug regimens to two-drug regimens.
ViiV Healthcare's VOGUE Phase 3b trial represents a critical inflection point that could reshape the global HIV treatment market, which is currently valued at approximately $34 billion annually. It is a direct attempt to demonstrate the clinical non-inferiority and reduced toxicity of Dovato (2025 sales of approximately $3.4 billion) compared to Biktarvy from Gilead Sciences (2025 sales of approximately $14.3 billion), the current market leader. Depending on the trial results, the patient population that prefers two-drug regimens due to concerns about long-term side effects may expand significantly, potentially leading to revisions in global treatment guidelines. In the short term, it will secure revenue growth for ViiV Healthcare's major shareholders, GSK and Pfizer, and in the medium to long term, it will challenge Gilead's dominant position by completely restructuring the treatment paradigm from a three-drug regimen to a two-drug regimen.
Source: ClinicalTrials.gov (api_ct)